Utilising similar antibodies targeting IGF2BP3, Jag1, Notch1/3, and Hes1 as a therapeutic strategy in pre‐existing liver fibrosis models would enhance the translational value of these discoveries. This evidence concerns the gene IGF2BP3 and Hepatic fibrosis.